2026 04 21 Intuitive Surgical Isrg Q1 2026 Earnings Call

Summary

Intuitive Surgical reported da Vinci procedure growth of 16% (847,000 total) and Ion lung biopsy procedures up 39% (43,000). The dominant causal driver is da Vinci 5 — its utilization exceeds the older Xi model, and the platform's ecosystem capabilities enable after-hours expansion (+31%). Internationally, reimbursement policy changes are the unlock: seven new procedure codes plus incremental financial support for high-volume robotic programs. China remains a structural headwind due to domestic competition and delayed reimbursement code implementation (2027 at earliest).

Transcript

David Rosa (President): "Growth was supported by a 31% increase in after-hours procedures and higher overall utilization. da Vinci 5 utilization continues to exceed that of da Vinci Xi, driving U.S. utilization growth to 4%."

David Rosa (President): "Outside the U.S., da Vinci procedures grew 19%, led by continued strength in general surgery and gynecology as adoption expands beyond urology."

David Rosa (President): "We are encouraged by recent policy developments, including incremental financial support for higher-volume robotic programs and new reimbursement for 7 additional procedures."

Jamie Samath (CFO): "Clinical publications continue to reinforce progress here, including a recent Mayo Clinic publication of approximately 2,000 patients, which demonstrated that use of Ion supports earlier identification of malignancy."

Jamie Samath (CFO): "China remains challenged by 'relatively low tender activity,' 'domestic competition and policy-driven pricing pressure,' and continued uncertainty about new reimbursement codes until at least 2027."

Jamie Samath (CFO): "While we did not see any significant impact on procedure volumes in Q1...we remain cautious as to what the potential impact, if any, might be" regarding ACA subsidy expirations.